

106

POSTER

Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients.

J. Akervall^{1,3}, X. Guo², M. Qian², J. Schoumans², J. Yuhas², T. Carey³, B. Leiser², C. Bradford³, J. Tennvall⁴, B. Teh². ¹ Lund University, Dept of Otolaryngology, Head and Neck Surgery, Lund, Sweden; ² Van Andel Research Institute, Lab of Cancer Genetics, Grand Rapids, Michigan, USA; ³ University of Michigan, Dept of Otolaryngology, Head and Neck Surgery, Ann Arbor, Michigan, USA; ⁴ Lund University, Dept of Oncology, Lund, Sweden

Treatment strategies for squamous cell carcinoma of the head and neck (SCCHN) are still based on TNM-classification. However, it is clear that biological features of the tumors have an independent impact on the clinical behaviour of SCCHN. Biomarkers may serve as predictive markers for clinical response to specific therapies. The aim of the present study was to examine genetic changes and gene expression profiles that might correlate with sensitivity to cisplatin (MTT assay) in 10 UM-SCC head and neck cancer cell lines. Five cisplatin-sensitive and five cisplatin-resistant cell lines were studied by comparative genomic hybridization (CGH), Spectral karyotyping (SKY), and cDNA microarray analysis. The five cisplatin-resistant cell lines demonstrated significantly more genetic imbalances (regions of loss and amplification) and chromosomal abnormalities than the five cisplatin-sensitive cell lines by CGH and SKY, respectively. Supervised clustering identified approximately 60 genes that clearly distinguish between the two groups of cell lines. Some of these genes are known to be involved in tumor progression, metastasis and drug resistance. By RT-PCR, we further confirmed the differential expressions of tissue inhibitor of metalloproteinase 2 (TIMP-2) and TIMP-3. Low expression of the oncogene c-met correlated with chemosensitivity (cDNA microarray). In a clinical material of 29 patients with SCCHN that received induction chemotherapy, low expression of c-met (immunohistochemistry), one of the gene from the distinguishing set was seen in flow cytometrically diploid tumors ($p < 0.01$) and tended to correlate with better disease-specific survival. We conclude that cisplatin sensitivity and resistance are related to distinctive differences in genetic and expression profiles in individual SCCHN tumor cell lines. The genes we have identified may serve as potential targets for novel treatment strategies.

107

POSTER

Phase II continuous 7 days per week irradiation concomitantly with chemotherapy in advanced head and neck tumors treatment.

T. Rutkowski, W. Sasiadek, A. Mucha, K. Skladowski, M. Sygula, M. Golen, W. Przorek, B. Pilecki. *MSC Cancer Center-Institute, I Radiotherapy Clinic, Gliwice, Poland*

Concomitant radiochemotherapy (CHRT) for locoregional advanced head and neck cancer (HNSCC) resulted in improved disease control and survival. DDP and vinorelbine are both active in HNSCC treatment likewise conventional radiotherapy regimes. This is probably the first schedule that combined continuous, accelerated radiotherapy (7 days per week) with chemotherapy.

Purpose: To assess the tolerance and efficacy of proposed schedule of concomitant CHRT for HNSCC.

Material and Methods: Eligible patients had previously untreated, histologically proven HNSCC of the T3-4, N2-3 stage. Forty one involved patients are males of 52 mean age in good general performance status. The primary disease sites are 19 oropharynx, 6 hypopharynx, 6 larynx, 4 linguae, 4 metastases from unknown primary site and 2 nasopharynx. Treatment consisted of DDP (100mg/m² administered in 1,22,43,64 day), vinorelbine (30 mg/m² in 1,8,22,29,43,50,64 day) continuously with accelerated (7 days a week) irradiation (started on 23 rd day) to the dose of 68 Gy in 40 fr. Due to toxicity of chemotherapy doses of DDP and vinorelbine were decreased to 70 and 20 respectively after first 23 patients.

Results: Results were studied among 40 patients. There was one death observed due to respiro-circulatory failure during treatment. Median follow-up was 20 months. Complete local and nodal regression was observed in 35 (87.5%) and 33 (82.5%) of patients respectively. Recidivation of the disease was observed in 2 patients (5%). Distant metastases were observed in 5 (15%) patients. There were 9 (22.5%) death due to disease. Treatment was well tolerated. The most frequent toxicity included anaemia (>2 in 8%), leucopenia (>2 in 25%) thrombocytopenia (>2 in 4%), acute mucositis acc. to Dische score was from the range of 11-22.

Conclusion: Proposed schedule is effective and well tolerated. Randomised study is however needed to confirm results.

108

POSTER

Stereotactic radiotherapy (SRT) plus external radiotherapy as radical treatment in nasopharyngeal carcinoma (NPC) with first local recurrence (LR), Queen Elizabeth hospital experience

F.Y. Cheung¹, P.F. So¹, Y.T. Fu¹, S. Yau¹, J. Lam², C. Chan². ¹ Queen Elizabeth Hospital, Clinical Oncology, Hong Kong, Hong Kong; ² Queen Elizabeth Hospital, Medical Physics, Hong Kong, Hong Kong

Background: First locally recurrent NPC was treated with re-irradiation in our institution. We used lower dose of external re-irradiation plus SRT, aiming to decrease serious long-term complication.

Introduction: This is a retrospective review of patients treated with radical external RT plus SRT in NPC patients with first LR from January, 1998 to May, 2002. Results including local control (LC), overall survival (OS), failure free survival (FFS) and complications of treatment were analyzed in March, 2003.

Method and Materials: 37 patients, 26 males and 11 females had radical reirradiation. Median age was 52.5. Histology showed 30 undifferentiated, 6 poorly differentiated and 1 moderately differentiated carcinoma. All patients were assessed by CT scans. 36 patients had MRI assessment. rT stage by UICC (1997) was: 5 T1, 7 T2a, 12 T2b, 10 T3 and 3 T4. 24 patients were treated with conformal RT, 50Gy in 17, 54Gy in 4 and 60Gy in 3. 13 patients received conventional 3 fields RT, 54Gy in 10 and 56Gy in 3. Majority SRT schedules comprised of 12Gy in 2 to 3 weekly fractions or 10Gy in 2 weekly fractions at 50-90% isodose lines. Median time from local control after the first course of RT to diagnosis of first LR was 29.7 months (4.7 to 150.9 months). Two types of follow up (FU) time were used. FU1 from diagnosis of first LR had median 28.5 months (9.0 to 55.1 months). FU2 from date of diagnosis NPC had median 59.0 months (29.1 to 196.5 months).

Results: No local failure for rT1 and rT2a patients at time of analysis. 5 had local failure, 2 in rT2b, 2 in rT3 and 1 in rT4. 3 patients had neck failure; 1 was salvaged by radical neck dissection and brachytherapy. 7 patients died, 3 from distant metastasis, 4 from complications. Treatment related death included 1 sudden death with exposed C1, 1 with uncontrolled maxillary artery bleeding, 1 sudden death with temporal lobe necrosis (TLN) and 1 due to aspiration pneumonia. Possible explanations for complications were hypofractionation in first course RT and too high cumulative dose contributed from first treatment, external reirradiation and SRT. By FU1, actuarial LC rate, OS rate and FFS rate at 2 years were 88.7%, 89.5% and 77.1% respectively. By FU2, actuarial LC rate, OS rate and FFS rate at 5 years were 93.7%, 85.3% and 77.2% respectively. 4 patients had TLN 9-42 months after reirradiation. 1 patient needed tube feeding and died of aspiration. 11 patients had cranial nerve palsies. 7 patients had different degrees of hearing loss. 10 patients had hypopituitarism.

Conclusion: The results showed that lower dose of external RT plus SRT achieved good local control in first LR NPC patients. However, survival was still limited by complication and distant metastasis. Complications might be decreased by (1) conformal RT < 54Gy/27fr, (2) SRT dose < 12Gy in 2 weekly fractions at 70% rather than 50% isodose level and (3) careful limitation of total dose received by vital structures.

109

POSTER

Cisplatin-DNA adduct measurements in head and neck cancer patients treated by chemoradiotherapy

F.J.P. Hoebbers¹, D. Pluim², H. Bartelink¹, A.J.M. Balm³, A.C. Begg², C.R.N. Rasch¹, J.H.M. Schellens⁴, M. Verheij¹. ¹ Netherlands Cancer Institute, Radiotherapy, Amsterdam; ² Netherlands Cancer Institute, Experimental Therapy, Amsterdam; ³ Netherlands Cancer Institute, Surgical Oncology, Amsterdam; ⁴ Netherlands Cancer Institute, Medical Oncology, Amsterdam, The Netherlands

Background: The optimal dose and route of administration for cisplatin-based chemoradiotherapy in patients with irresectable locally advanced stage IV head and neck cancer (H&N) of the pharynx or oral cavity is currently subject of investigation in a randomized phase III trial. This trial compares selective intra-arterial (i.a.) supradose cisplatin (150 mg/m²) (with systemic rescue by sodium-thiosulfate) and systemic intravenous (i.v.) cisplatin (100 mg/m²). Both arms are combined with standard fractionated radiotherapy (70 Gy/7 weeks). In a previous study in non-small cell lung cancer it was shown that cisplatin-DNA adducts were of predictive value for treatment outcome after chemoradiation. In a subgroup of patients entered in the current trial we studied levels of cisplatin-DNA adducts in primary tumor and normal tissue.

Material and methods: After written informed consent, we obtained buccal cells, white blood cells (WBC) and/or a tumor biopsy before and 23

hours after the end of the first course of chemoradiotherapy. Adduct levels were determined by immunocytochemistry using the polyclonal antibody NK1 A-59 for the buccal cells. A 32 P-postlabeling technique was used to quantify selectively the major cisplatin-DNA adducts (GG and AG adducts) in WBC and tumor.

Results: So far, in 16 patients, adduct levels have been measured; 10 after i.v. and 6 after i.a. cisplatin infusion. Tumor sites were oropharynx (n=10), oral cavity (n=3) and hypopharynx (n=3). Normal tissue samples were obtained from all 16 patients, primary tumor from 10 patients with tumors, accessible for biopsy. See table for results of the adduct-levels in tumor and WBC.

Chemotherapy- regime, concurrently with RT:		Cisplatin-DNA adducts (in fmol/ μ g DNA) in:			
		WBC		Tumor	
		GG	AG	GG	AG
100 mg/m ² i.v.	mean	0,929	0,117	3,946	0,388
	SD	0,249	0,036	1,183	0,067
150 mg/m ² i.a.	mean	0,826	0,093	4,070	0,373
	SD	0,211	0,028	0,523	0,145

The difference between adduct levels in WBC and primary tumor was statistically significant ($p < 0.02$) for both the i.a. and i.v. treated patients. There were no differences in adduct levels in either WBC or tumor between the i.a. and i.v. group. Analysis of adducts in buccal cells is ongoing.

Conclusions: Cisplatin-DNA adduct levels in primary tumor of H&N cancer are 4-fold increased compared to WBC, both after supradose i.a. and conventional i.v. cisplatin-based chemoradiation. Despite the selective supradose i.a. administration of cisplatin, adduct levels in primary tumor are comparable to levels obtained after conventional i.v. cisplatin. Whether cisplatin-DNA adduct levels correlate with treatment outcome, is subject of current research.

110

POSTER

Cisplatin + vinorelbine in recurrent salivary gland malignancies: final report on 42 cases

M. Airolidi, S. Marchionatti, F. Pedani, C. Bumma. *S. Giovanni Antica Sede Hospital, Medical Oncology Department, Torino, Italy*

In a randomized trial we have shown that cisplatin (DDP) + vinorelbine (VNB) is superior to VNB alone in recurrent Salivary Gland Malignancies (SGM) (Cancer 91:541-7:2001), although results on a large number of pts are lacking. Here we report final results of this combination. Between April 1993 and February 2001 42 pts (35 m, 17 f; median age= 57 yrs; median ECOG PS= 1) affected by recurrent/metastatic SGM (major SG = 23 pts, minor SG = 19 pts / adenocarcinoma = 10 pts; adenoid cystic ca. =27, malignant mixed t. =1; undifferentiated ca.=3; mucoepidermoid ca.=1 / local recurrence = 18 pts, local + mts =7, mts only =17) have been treated with DDP 80 mg/m², on day 1 plus VNB 25 mg/m² on day 1 and 8 (every 3 weeks for a minimum of 3 cycles). All pts had received a loco-regional treatment (surgery + radiation =36 pts; surgery =3; radiotherapy =3) and 12 pts had received a first line DDP-based chemotherapy. Results of first line DDP+VNB (30 cases): 4 CR (13%), 8 PR (27%), 11 NC (37%) and 7 PD (23%); median CR duration =15 months (6-28); median PR duration =7.5 m (3-11); median overall survival =10 months (range=3-29; CR=19 m.; PR=12.5 m). Results of second line DDP+VNB (12 pts) =2 PR (17%), 4 NC (33%) and 6 PD (50%); median PR duration =4 m.; median overall survival =5 m. (1-12). Toxicity (42 pts): G3: nausea/vomiting 7%, leukopenia 12%; G2: nausea/vomiting 50%, leukopenia 19%, thrombocytopenia 7%, anemia 7%, peripheral neurotoxicity 7%. In conclusion DDP+VNB is an active first line combination for recurrent/metastatic SGM with acceptable toxicity; the clinical role of this scheme in second line therapy is poor.

111

POSTER

Early stage oral cavity squamous cell carcinoma

T.M. Chen^{1,3}, J.T. Chang^{2,3}, I.H. Chen^{1,3}, C.J. Kang^{1,3}, C.T. Liao^{1,3}.

¹ Chang Gung Memorial Hospital, ENT and Head & Neck Surgery, Taoyuan, Taiwan; ² Chang Gung Memorial Hospital, Radiation Oncology, Taoyuan, Taiwan; ³ Chang Gung Memorial Hospital, Taipei Chang Gung Head & Neck Oncology Group, Taoyuan, Taiwan

Introduction: To evaluate the treatment result of early stage oral cavity cancer and assess the importance of elective neck dissection

Material and Methods: There were 781 clinical stage I-II oral cavity cancer received radical surgery in Chang Gung Memorial Hospital from April 1, 1994 to July 31, 2002. The median age was 50 (ranging from 23

to 85) and 712 (91.2%) are male, 69 (8.8%) are female. Only 88 (11%) patients are without smoking, alcohol and/or beta1 quid exposure. Seven hundred and fifty seven (96.9%) patients received CT or MRT as staging modality. Three hundred and sixty (46.1%) patients were T1 lesion and 421 (53.9%) were T2 lesion. The site distribution was tongue: 397 (50.7%), gum: 30(3.8%), palate: 51(6.5%), cheek: 223(28.6%), retromolar: 28(3.6%), lip: 22(2.8%), and mouth floor: 30(3.8%). Four hundred and eighty eight (62.5%) patients received elective supra-omohyoid neck dissection. Free tissue flap was performed after excision by plastic surgeons. One hundred and twenty nine (16.5%) patients received postoperative radiotherapy.

Result: N stage change is noted in 58 (11.9%) patients after neck dissection. There are 12 (6.6%) patients in T1 lesions and 46 (15.1%) in T2 lesions ($p=0.008$). T upstage is noted in 25 patients after operation. Bone invasion is found in 11 (1.4%) patients. The 5-year overall survival for clinical stage I is 83.8% and 79.4% for stage II ($p=0.06$). The 5-year overall survival for pathological stage I is 78.6%, stage II: 73.4%, III-IV: 71.2% ($p=0.002$). Neck operation or not has no significant survival difference in overall survival (79.66% vs. 72.3%, $p=0.161$) but significant difference in loco-regional recurrence (32.4% vs. 18.9%, $p=0.000$). However, in the tongue cancer patients, neck operation has significant survival benefit. (84.6% vs. 75.6%, $p=0.047$) and no difference in other subsites.

Conclusion: There are about 12% of patients will become positive neck lymphadenopathy after elective neck dissection in clinical stage I-II patients. Elective neck dissection may be considered in early stage oral cavity cancer to improve loco-regional control especially for tongue cancer that neck dissection may improve survival.

112

POSTER

Head and neck reconstruction in oncology

M. Ribeiro, C. Sanches, D. Cunha, F. Sousa, D. Brito, E. Monteiro, J.L. Pontes. *Instituto Português de Oncologia - Centro do Porto, Surgical Oncology Department, Porto, Portugal*

Introduction: Advanced carcinomas involving head and neck present a major therapeutic challenge because of their poor prognosis, the frequently associated medical problems of the patients, and the adverse effect of treatment on oral and pharyngeal function. Therapeutic techniques combining multiple treatment modalities are commonly employed for patients with advanced disease. Modern reconstructive techniques allow immediate reconstruction and better functional outcomes, while allowing the patients to progress through to multimodality treatment in a timely manner.

Material and Methods: Between February 1990 and March 2003 we performed head and neck reconstructions in 412 patients (M-353/F-59) with myocutaneous flaps, 26 of which were full-thickness defects. To repair these defects we have used the following 426 flaps: Pectoralis major 297; Trapezius myocutaneous flap 39; Sternocleidomastoid 4; Platysma 8;

